Lakewood-Amedex Biotherapeutics Inc.
LABTNasdaqCIK 2079272HealthcareFiscal year ends Dec 31
Reports and events: 15 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-2917:49 ET | 8-K | 5.07 Shareholder vote results | 0001213900-26-104177 |
| 2026-09-1817:30 ET | S-1 | Registration statement | 0001213900-26-101512 |
| 2026-08-1421:36 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001213900-26-089380 |
| 2026-08-1017:13 ET | DEF 14A | Proxy statementPeriod 2026-09-22 | 0001213900-26-087336 |
| 2026-07-1516:15 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-078328 |
| 2026-06-1711:40 ET | 8-K | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001213900-26-069512 |
| 2026-05-2216:55 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001213900-26-060640 |
| 2026-05-0116:05 ET | S-1 | Registration statement | 0001213900-26-050936 |
| 2026-04-2816:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-048553 |
| 2026-04-0611:38 ET | S-1/A | Registration statement, amended | 0001213900-26-040254 |
| 2026-04-0106:20 ET | S-1/A | Registration statement, amended | 0001213900-26-037938 |
| 2026-03-1116:45 ET | S-1/A | Registration statement, amended | 0001213900-26-026195 |
| 2026-02-1321:56 ET | S-1/A | Registration statement, amended | 0001213900-26-015814 |
| 2026-02-0521:35 ET | S-1/A | Registration statement, amended | 0001213900-26-012492 |
| 2026-01-0917:28 ET | S-1 | Registration statement | 0001213900-26-003037 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.